All In Biotech

Drug Trial Radar · NCT04355689

Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome

Safety and Efficacy of NPI-001 Tablets Versus Placebo for Treatment of Retinitis Pigmentosa Associated With Usher Syndrome

Last checked: Nov 19, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

49

Actual

Start

Sep 3, 2020

Primary completion

Jun 20, 2025

Study completion Apr 22, 2026

Sponsor

Lead sponsor
Nacuity Pharmaceuticals, Inc.Industry
Sponsor type
Industry
Collaborators
Foundation Fighting Blindness; Nacuity Pharmaceuticals, PTY LTD
First posted
Apr 21, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will examine the safety and efficacy of NPI-001 Tablets as compared to placebo for 24 months in subjects with vision loss due to RP associated with Usher syndrome.

Conditions

  • Usher Syndromes

Interventions

  • NPI-001Drug

    oral tablet

  • PlaceboOther

    Placebo tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate change from baseline for retinal sensitivity assessed by microperimetry of active versus placeboTime frame: 24 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Queensland Eye Institute

    Brisbane, Australia

  • CERA

    Melbourne, Australia

  • Lions Eye Institute

    Perth, Australia

  • Sydney Eye Hospital / Save Sight Institute

    Sydney, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.